Who is sponsoring NCT04128137?

NCT04128137 is sponsored by H.A.C. PHARMA.

What condition does NCT04128137 study?

NCT04128137 studies Neurogenic Orthostatic Hypotension.

What drugs are being tested in NCT04128137?

Interventions: Fludrocortisone, Placebo.

What is the status of NCT04128137?

NCT04128137 is currently UNKNOWN.

Last reviewed 2023-09-29 · How we verify

Evaluation of Efficacy and Tolerance of Fludrocortisone (Flucortac) in the Treatment of Orthostatic Neurogenic Hypotension

NCT04128137 Phase 4 UNKNOWN

To evaluate the efficacy of a 4-week fludrocortisone (FLU) treatment on systolic blood pressure depression after 5 minutes of active orthostatism in patients with neurogenic orthostatic hypotension (HON) symptomatic, despite treatment with non-drug measures with or without midodrine.

Details

Lead sponsor	H.A.C. PHARMA
Phase	Phase 4
Status	UNKNOWN
Enrolment	90
Start date	2020-07-09
Completion	2024-06

Conditions

Neurogenic Orthostatic Hypotension

Interventions

Fludrocortisone
Placebo

Primary outcomes

Systolic BP diminution — 8 weeks
Systolic BP diminution when moving from supine to standing, measured with a semi-automatic blood pressure monitor \- AP in upright position: the lowest value of the measurements obtained every minute, for 5 minutes after rising.

Countries

France